EA202190136A1 - Способ очистки антигена - Google Patents

Способ очистки антигена

Info

Publication number
EA202190136A1
EA202190136A1 EA202190136A EA202190136A EA202190136A1 EA 202190136 A1 EA202190136 A1 EA 202190136A1 EA 202190136 A EA202190136 A EA 202190136A EA 202190136 A EA202190136 A EA 202190136A EA 202190136 A1 EA202190136 A1 EA 202190136A1
Authority
EA
Eurasian Patent Office
Prior art keywords
purification method
antigen purification
antigen
compositions
processes
Prior art date
Application number
EA202190136A
Other languages
English (en)
Inventor
Кунал Бакши
Марцин Кшиштоф Буньо
Сумана Чандрамоули
Мэттью Альберт Тайсон
Цзыхао Ван
Марк Джонатан Уилсон
Original Assignee
Глаксосмитклайн Байолоджикалс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс Са filed Critical Глаксосмитклайн Байолоджикалс Са
Publication of EA202190136A1 publication Critical patent/EA202190136A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Abstract

Предложены способы, композиции, процессы и виды применения, относящиеся к рекомбинантному растворимому полипептиду белка F RSV.
EA202190136A 2018-07-31 2019-07-30 Способ очистки антигена EA202190136A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712280P 2018-07-31 2018-07-31
PCT/IB2019/056501 WO2020026147A1 (en) 2018-07-31 2019-07-30 Antigen purification method

Publications (1)

Publication Number Publication Date
EA202190136A1 true EA202190136A1 (ru) 2021-05-14

Family

ID=68084873

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190136A EA202190136A1 (ru) 2018-07-31 2019-07-30 Способ очистки антигена

Country Status (13)

Country Link
US (1) US20210292395A1 (ru)
EP (1) EP3829618A1 (ru)
JP (1) JP2021532764A (ru)
KR (1) KR20210038919A (ru)
CN (1) CN112566654A (ru)
AU (1) AU2019313502A1 (ru)
BR (1) BR112020027090A2 (ru)
CA (1) CA3106304A1 (ru)
EA (1) EA202190136A1 (ru)
IL (1) IL280140A (ru)
MX (1) MX2021001129A (ru)
SG (1) SG11202100194VA (ru)
WO (1) WO2020026147A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022023813A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
JP2022023814A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
CN116621948B (zh) * 2023-07-21 2023-10-13 易康生物(苏州)有限公司 一种重组呼吸道合胞病毒f蛋白的纯化工艺方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2486938T3 (pl) 2006-09-26 2018-08-31 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
BR112013014598A2 (pt) 2010-12-14 2017-09-19 Glaxosmithkline Biologicals Sa composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênica estável, e, kit
WO2014160463A1 (en) 2013-03-13 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prefusion rsv f proteins and their use
CA3015570A1 (en) * 2016-03-29 2017-10-05 Peter Kwong Substitutions-modified prefusion rsv f proteins and their use

Also Published As

Publication number Publication date
SG11202100194VA (en) 2021-02-25
JP2021532764A (ja) 2021-12-02
BR112020027090A2 (pt) 2021-03-30
IL280140A (en) 2021-03-01
CA3106304A1 (en) 2020-02-06
WO2020026147A1 (en) 2020-02-06
EP3829618A1 (en) 2021-06-09
US20210292395A1 (en) 2021-09-23
MX2021001129A (es) 2021-07-02
CN112566654A (zh) 2021-03-26
AU2019313502A1 (en) 2021-01-28
KR20210038919A (ko) 2021-04-08

Similar Documents

Publication Publication Date Title
EA202190136A1 (ru) Способ очистки антигена
BR112021020023A2 (pt) Ligantes de conjugação melhorados
AU2020346959B2 (en) Methods and compositions for protein and peptide sequencing
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
MX2020010199A (es) Polipeptidos antigenicos del virus sincitial respiratorio.
PE20230381A1 (es) Proteina de union a rgma
EA202090262A1 (ru) Очистка белка
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
MX2023005421A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
EP3805246A4 (en) METHODS OF PURIFICATION OF LONG-CHAIN POLYPEPTIDES
EA202090404A1 (ru) Универсальный способ презентирования циклического пептида на белковой структуре
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
EA201790725A1 (ru) Основанные на близости расположения способы выбора партнеров для связывания
EA201892524A1 (ru) Днк-моноклональные антитела, нацеленные на il-6 и cd126
EA202191470A1 (ru) Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения
EA202091916A1 (ru) Способ и устройство расщепления бобовых
EA201790241A1 (ru) Эффективная селективность в отношении рекомбинантных белков
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение
EA201891747A1 (ru) Полинуклеотиды и полипептиды slam и их использование
RU2017104770A (ru) МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, СПЕЦИФИЧНОЕ К ЭПИТОПУ БЕЛКА р17 ВИЧ-1
EA202090583A1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии